Cargando…
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
Carcinomas of an unknown primary site (CUP) are heterogeneous tumours with a median survival of only 8 months. Tyrosine kinase inhibitors are promising new drugs. The aim of this study was to determine the expression of EGF-receptor, Her-2/neu, and c-Kit tyrosine kinases in CUP. Paraffin-embedded sp...
Autores principales: | Massard, C, Voigt, J-J, Laplanche, A, Culine, S, Lortholary, A, Bugat, R, Theodore, C, Priou, F, Kaminsky, M-C, Lesimple, T, Pivot, X, Coudert, B, Douillard, J-Y, Merrouche, Y, Fizazi, K |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360401/ https://www.ncbi.nlm.nih.gov/pubmed/17876336 http://dx.doi.org/10.1038/sj.bjc.6603942 |
Ejemplares similares
-
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
por: Massard, C, et al.
Publicado: (2008) -
Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)
por: Bugat, R, et al.
Publicado: (2003) -
ErbB2/HER2/Neu resembles an autoinhibited invertebrate EGF receptor
por: Alvarado, Diego, et al.
Publicado: (2009) -
Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients
por: Ady, N, et al.
Publicado: (2004) -
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
por: Farace, F, et al.
Publicado: (2011)